TRICAPRYLIN

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
471.0 7.1 0 6 79.0 23 0.89
CAS
538238
UNII
6P92858988
SYNONYMS
ZINC ID(s)
Availability
Present in 33 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT01211782 AC-1204 Long-term Efficacy Response Trial (ALERT Protocol) Phase 2/Phase 3 Withdrawn
NCT02260973 2014-11-01 The Influence of PRN Omega-3 Nutritional Supplement on Visual Acuity Phase 2/Phase 3 Not Yet Recruiting
NCT02376621 2014-10-01 Bioavailability of Omega-3 Food Supplements in Healthy Subjects Phase 1 Completed
NCT02248948 2014-09-01 Superiority of Omega-3 Versus Placebo on the Improvement of ADHD in Children Phase 4 Recruiting
NCT02260960 2014-03-01 The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease Phase 2/Phase 3 Recruiting
NCT01848327 2013-02-01 Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis Phase 2 Recruiting
NCT02005900 2011-06-01 Effect of DHA on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in HIV Patients Under HAART. Phase 3 Completed
NCT01252979 2010-12-01 Ketones & Mitochondrial Heteroplasmy Phase 0 Completed
NCT02201368 2009-11-01 Triheptanoin Treatment Trial for Patients With Long-chain Fatty Acid Beta-oxidation Defects Phase 3 Withdrawn
NCT00959010 2008-10-01 Omega 3 Supplementation in Cystic Fibrosis Patients Phase 3 Recruiting
NCT00644098 2008-09-01 Effect of a Soluble Fibre Blend and Medium Chain Triglycerides on Body Composition and Cardiometabolic Risk Factors Phase 2 Completed
NCT00672763 2008-05-01 Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease Phase 4 Withdrawn
NCT00292279 2002-06-01 The Impact of Omega-3 Fat Emulsion on Clinical Outcome of Post-Operative Cancer Patients Phase 3 Completed

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Epidural Injection, Suspension, Liposomal 0.03%
Infiltration Injection, Liposomal 0.2%
Oral Tablet, Extended Release 0.45MG

More Information

Usage Over Time

Comments